PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 16, 2026Materials & Design0 citationsOpen Access

Tacrolimus@ZIF-8/HTCC eye drop mediated transcorneal delivery of tacrolimus for preventing high-risk keratoplasty rejection

View Full Paper
DJDadong JiaMLMingshuang LiMQMian Qin

Key Points

  • To develop a transcorneal delivery system for tacrolimus to prevent immune-mediated graft rejection in keratoplasty.
  • Developed FK506@ZIF-8 nanoparticles (<100 nm) with 4.5% drug-loading capacity.
  • Mixed nanoparticles with 2-hydroxypropyltrimethyl ammonium chloride chitosan to enhance retention.
  • Performed in vitro release studies and biocompatibility tests in human corneal cells.
  • Prolonged graft survival observed in rabbit model with FK506@ZIF-8/HTCC eye drops.
  • Inhibition of inflammatory infiltration compared to conventional FK506 drops.
  • Sustained drug release confirmed over 24 hours with minimal ocular irritation.

Abstract

• The tacrolimus@ zeolitic imidazolate framework-8 nanoparticles (240 min retention) synergistically enhanced transcorneal delivery of FK506. In a rabbit IMGR model, the FK506@ZIF-8/HTCC eye drop significantly prolonged graft survival, reduced inflammatory infiltration, and outperformed conventional FK506 eye drops, highlighting its therapeutic potential for overcoming corneal drug delivery barriers. In summary, the FK506@ZIF-8/HTCC sol hold great promise for preventing high-risk keratoplasty rejection in clinic in the future.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jia et al. (2026) studied this question.

synapsesocial.com/papers/6a080ae2a487c87a6a40cdbbhttps://doi.org/10.1016/j.matdes.2026.116223
Ask AI
Helpful
Bookmark
Share
View Full Paper